Work Here?
Capricor Therapeutics
Work Here?
Biotech developing cell- and exosome therapeutics
Capricor Therapeutics
Work Here?
Biotech developing cell- and exosome therapeutics
Overview
Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.
About Capricor Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Beverly Hills, California
Founded
2005
Simplify's Take
What believers are saying
- FDA approval expected August 22, 2026 enables rapid market entry and revenue generation.
- Manufacturing facility passed FDA pre-license inspection; capacity scales to 2,500 patients annually.
- $318 million cash runway funds operations through Q4 2027 post-launch commercialization.
What critics are saying
- FDA rejects Deramiocel BLA again by August 22, 2026 due to manufacturing deficiencies.
- Sarepta's Elevidys gene therapy captures 80% DMD market share within 24 months.
- EVP insider share sales signal management doubts; stock drops 50% pre-approval decision.
What makes Capricor Therapeutics unique
- First therapy delivering statistically significant upper limb function improvement in DMD.
- Rare Pediatric Disease Designation qualifies Capricor for valuable Priority Review Voucher.
- Exclusive US and Japan commercialization partnership with Nippon Shinyaku validates market potential.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$361.6M
Above
Industry Average
Funded Over
15 Rounds
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Unlimited Paid Time Off
Flexible Work Hours
Paid Vacation
Staff Training (not in predefined)
Stock Price
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 2%2 year growth
↓ -3%SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...
HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...
Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...
Capricor Therapeutics is Hiring for 32 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Capricor Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Beverly Hills, California
Founded
2005
Capricor Therapeutics is Hiring for 32 Jobs on Simplify!
Find jobs on Simplify and start your career today